Sihuan Pharmaceutical Holdings Group (HK:0460) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sihuan Pharmaceutical Holdings Group Ltd. has announced that its subsidiary, Huisheng Biopharmaceutical, received acceptance from China’s NMPA for their new Semaglutide injection, aimed at treating weight loss. This once-weekly injectable drug not only helps reduce blood sugar levels but also aids in weight loss, blood pressure reduction, and improving blood lipid profiles, with the potential to lower major cardiovascular risks. The global sales for Semaglutide have seen a surge, with a 400% increase in 2023 for the weight loss market alone.
For further insights into HK:0460 stock, check out TipRanks’ Stock Analysis page.